Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has experienced a significant stock price increase, with a 5% rise on March 27, reaching 53.32 CNY per share, and a cumulative increase of 6.82% over three consecutive days [1][5]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1][6]. - The main business activities include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1][6]. - The revenue composition of the main business is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1][6]. Fund Holdings - Three funds under Huatai-PineBridge have significant holdings in Tiger Med, totaling 3.0177 million shares. Based on the previous day's closing price of 50.78 CNY, the current stock price of 53.32 CNY results in a floating profit of approximately 7.6649 million CNY for the day and 9.7772 million CNY over the three-day increase [2][7]. - The specific fund holdings include: - Huatai-PineBridge CSI Biotech Index (LOF) A: 1.2511 million shares, representing 3.22% of the fund's net value, with a recent increase of 31,900 shares [3][8]. - Huatai-PineBridge Precision Medicine Index (LOF) A: 1.0487 million shares, representing 5.51% of the fund's net value, newly entered [4][9]. - Huatai-PineBridge National Biomedicine ETF: 717,879 shares, representing 5.67% of the fund's net value, with an increase of 235,200 shares [4][9].